Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Inovio Pharmaceuticals Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $41.41, while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GPTY | INO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $2.87 |
52-Week Low | $34.73 | $1.05 |
Market Cap | — | $96.26M |
Enterprise Value | — | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $41.41, down 3.97% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.30 to $0.38. Support and resistance levels cluster tightly around $43-$46, indicating potential for near-term consolidation. Recent news highlights focus on its option-income strategy and comparisons to peers like ULTY.
The outlook balances high yield potential against market volatility risks. Investment appeal centers on AI/tech exposure coupled with income generation, but reliance on semiconductor momentum and option premiums introduces volatility. Key risks include NAV erosion from the covered call strategy and sector concentration, requiring careful risk assessment for income-focused investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
